Acute ischemic stroke
Conditions
Interventions
None listed
Sponsors
Stryker Japan K.K.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients aged >= 20 years 2. Patients treated with Trevo Retriever as a thrombectomy device in first-line treatment - Those with first pass using the Trevo Retriever alone or in combination with an aspiration catheter - Excluding those with first pass using another thrombectomy device (stent retriever/aspiration catheter) - A PTA balloon is not considered a thrombectomy device. 3. Patients who gave informed consent or whose legally acceptable representative gave informed consent 4. Patients expected to be evaluable for the 90-day observation period after the procedure
Exclusion criteria
Exclusion criteria: Patients treated with a medical device that is unapproved in Japan
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy Effective blood flow reperfusion rate at the end of the whole procedure (defined as mTICI >= 2b) | — |
Secondary
| Measure | Time frame |
|---|---|
| Efficacy Degree of independence in daily living 90 days after the procedure (defined as mRS <= 2) Safety - Rate of worsening of neurological symptoms within 24 hours after the procedure (defined as exacerbation of NIHSS >= 4) - Incidence of symptomatic intracranial bleeding within 24 hours after the procedure - All-cause mortality within 90 days after the procedure - Incidence of adverse events related to the Trevo Retriever | — |
Countries
Japan
Contacts
Public ContactYoko Konuki
A2 Healthcare Corporation Clinical Development Department 4
Outcome results
None listed